for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hikma Pharmaceuticals Plc

HIK.L

現在値

2,459.00GBp

変化

--(--)

本日のレンジ

--

 - 

--

52週レンジ

2,158.00

 - 

2,768.00

∙ 約20分前の相場を表示しています。

適時開示

Hikma Pharmaceutical Agreed To Acquire Custopharm Inc From Water Street Healthcare Partners

Sept 27 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::HIKMA PHARMACEUTICAL - HIKMA ACQUIRES CUSTOPHARM.HIKMA PHARMACEUTICAL - HIKMA ACQUIRES CUSTOPHARM.HIKMA - AGREED TO ACQUIRE CUSTOPHARM INC. ('CUSTOPHARM') FROM WATER STREET HEALTHCARE PARTNERS.HIKMA - HIKMA WILL PAY AN INITIAL CASH CONSIDERATION OF $375 MILLION ON A DEBT AND CASH-FREE BASIS.HIKMA - HIKMA WILL PAY AN INITIAL CASH CONSIDERATION OF $375 MILLION.HIKMA - FURTHER $50 MILLION IN CONTINGENT CONSIDERATION PAYABLE UPON ACHIEVEMENT OF CERTAIN COMMERCIAL MILESTONES.HIKMA - EXPECTS IT TO GENERATE FULL YEAR 2021 REVENUE IN EXCESS OF $80 MILLION AND FOR ACQUISITION TO BE ACCRETIVE TO HIKMA'S INJECTABLES OPERATING MARGIN.

Bio-Thera And Hikma Announce Exclusive Agreement

Aug 27 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::HIKMA PHARMACEUTICAL - BIO-THERA AND HIKMA ANNOUNCE EXCLUSIVE AGREEMENT.HIKMA - ENTERED INTO A COMMERCIALIZATION AND LICENSE AGREEMENT TO COMMERCIALIZE BAT2206.HIKMA - BIO-THERA IS ELIGIBLE FOR AN UPFRONT PAYMENT OF $20 MILLION AS WELL AS FURTHER DEVELOPMENT AND COMMERCIAL MILESTONES OF UP TO $130 MILLION..HIKMA - BIO-THERA IS ELIGIBLE FOR AN UPFRONT PAYMENT OF $20 MILLION AS WELL AS FURTHER DEVELOPMENT AND COMMERCIAL MILESTONES OF UP TO $130 MILLION.HIKMA - AGREEMENT TO COMMERCIALIZE BAT2206.HIKMA - UNDER AGREEMENT, BIO-THERA WILL MAINTAIN RESPONSIBILITY FOR DEVELOPMENT, MANUFACTURING, AND SUPPLY OF BAT2206.HIKMA - HIKMA WILL HAVE EXCLUSIVE RIGHTS TO COMMERCIALIZE PRODUCT IN US.

Bio-Thera Solutions & Hikma Announce Exclusive Commercialization And License Agreement For Bat2206 In The U.S.

Aug 27 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::BIO-THERA SOLUTIONS AND HIKMA PHARMACEUTICALS ANNOUNCE EXCLUSIVE COMMERCIALIZATION AND LICENSE AGREEMENT FOR BAT2206 IN THE US, A PROPOSED BIOSIMILAR REFERENCING STELARA® (USTEKINUMAB).HIKMA - UNDER AGREEMENT, BIO-THERA WILL MAINTAIN RESPONSIBILITY FOR DEVELOPMENT, MANUFACTURING, AND SUPPLY OF BAT2206.HIKMA - HIKMA WILL HAVE EXCLUSIVE RIGHTS TO COMMERCIALIZE BAT2206 IN U.S..HIKMA - BIO-THERA IS ELIGIBLE FOR AN UPFRONT PAYMENT OF $20 MILLION AS WELL AS FURTHER DEVELOPMENT AND COMMERCIAL MILESTONES OF UP TO $130 MILLION.HIKMA - AGREEMENT WITH BIO-THERA PROVIDES HIKMA WITH A FIRST-RIGHT-TO-NEGOTIATE TO ADD EUROPE (EXCLUDING CIS COUNTRIES).

Hikma Pharma H1 Core Pretax Profit Rises

Aug 6 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::HIKMA PHARMACEUTICAL - HALF-YEAR REPORT.H1 CORE PRETAX PROFIT 285 MILLION USD VERSUS 265 MILLION USD YEAR AGO.HIKMA - HY REVENUE $1,216 MILLION VERSUS $1,132 MILLION.HIKMA - CONTINUING TO BENEFIT FROM INVESTMENTS WE HAVE MADE TO BUILD OUR PIPELINE OF NEW MEDICINES.HIKMA - WE NOW EXPECT FY GENERICS REVENUE TO BE IN RANGE OF $810 MILLION TO $830 MILLION AND CORE OPERATING MARGIN TO BE IN RANGE OF 22% TO 24%.HIKMA - FULL YEAR EXPECTATIONS FOR OUR INJECTABLES AND BRANDED BUSINESS, REMAIN SAME AS PREVIOUSLY GUIDED.

Hikma Pharmaceutical Announces US FDA Approval Of KLOXXADO

April 30 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::HIKMA PHARMACEUTICAL - HIKMA ANNOUNCES US FDA APPROVAL OF KLOXXADO.

Hikma Pharma Sees FY Generics Rev Towards Top End Of Outlook Range of $770 Mln-$810 Mln

April 30 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::HIKMA PHARMACEUTICAL - TRADING STATEMENT.HIKMA - FULL-YEAR OUTLOOK FOR GROUP IS UNCHANGED.HIKMA - GLOBAL INJECTABLES BUSINESS IS PERFORMING WELL.HIKMA - IN US, NEW PRODUCT LAUNCHES AND DEMAND FOR OUR BROADER PORTFOLIO ARE PARTIALLY OFFSETTING REDUCED DEMAND FOR COVID-19 RELATED PRODUCTS.HIKMA - IN EUROPE, WE ARE SEEING GOOD DEMAND FROM RECENT LAUNCHES AND CONTRACT MANUFACTURING.HIKMA - ALSO MADE GOOD PROGRESS IN EXPANDING OUR GLOBAL INJECTABLES PIPELINE,.HIKMA - CONTINUE TO EXPECT GLOBAL INJECTABLES CORE REVENUE TO GROW IN MID-SINGLE DIGITS AND CORE OPERATING MARGIN TO BE IN RANGE OF 37% TO 38%.HIKMA - EXPECT OUR FULL YEAR GENERICS REVENUE TO BE TOWARDS TOP END OF OUR GUIDANCE RANGE OF $770 MILLION TO $810 MILLION.HIKMA - EXPECT OUR FULL YEAR GENERICS CORE OPERATING MARGIN TO BE AROUND 20%..

Hikma, Melinta Therapeutics Sign Licensing Agreement For Two Novel Anti-Infectives For Middle East And North Africa Regions

April 29 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::HIKMA - CO AND MELINTA THERAPEUTICS SIGN EXCLUSIVE LICENSING AGREEMENT FOR TWO NOVEL ANTI-INFECTIVES FOR MIDDLE EAST AND NORTH AFRICA REGION.HIKMA - LICENSING AGREEMENT FOR VABOMERE AND ORBACTIV.

Hyloris: Partnership With Hikma For U.S. Commercialisation Of Maxigesic IV

April 28 (Reuters) - HYLORIS PHARMACEUTICALS SA <HYL.BR>::HYLORIS ANNOUNCES MAJOR COMMERCIAL PARTNERSHIP IN THE U.S. FOR MAXIGESIC® IV WITH HIKMA PHARMACEUTICALS <<<HIK.L>>>.IS ELIGIBLE TO RECEIVE $4 MLN IN REGULATORY BASED MILESTONES AS WELL AS COMMERCIAL MILESTONES AND A SHARE OF NET PROFIT.TO COMMERCIALISE MAXIGESIC IV IN U.S..MAXIGESIC IV HAS POTENTIAL TO COMBAT OPIOID EPIDEMIC IN PAIN MANAGEMENT.

AFT Pharmaceuticals Signs Exclusive License Agreement With Hikma Pharmaceuticals USA

April 28 (Reuters) - AFT Pharmaceuticals Ltd <AFT.NZ>::SIGNED EXCLUSIVE LICENSE & DISTRIBUTION AGREEMENT WITH HIKMA PHARMACEUTICALS USA.AGREEMENT FOR COMMERCIALISATION OF MAXIGESIC IV IN US.UNDER AGREEMENT, HIKMA WILL HAVE EXCLUSIVE RIGHTS FOR SALES, MARKETING, AND DISTRIBUTION OF MAXIGESIC IV IN US.CO TO BE ENTITLED TO UPFRONT, REGULATORY & COMMERCIAL MILESTONE PAYMENTS OF UP TO US$18.8 MLN.

Hikma And GSK Agree To Cease Potential Acquisition

March 11 (Reuters) - Hikma Pharmaceuticals PLC <HIK.L>::HIKMA PHARMACEUTICAL - HIKMA AND GSK AGREE TO CEASE POTENTIAL ACQUISITION.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up